Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03253926 · ClinicalTrials.gov registry record · Phase 1
Effect of Lorcaserin on Cannabis Withdrawal and Self-administration
A Phase 1 study of Cannabis Use, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT03253926: Completed Phase 1 study of Cannabis Use, sponsored by New York State Psychiatric Institute.
NCT03253926 is a Phase 1 study of Cannabis Use that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 15 participants, below the 279-participant average among 44 other Cannabis Use trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03253926, a Phase 1 study of Cannabis Use, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, the investigators are interested in testing how lorcaserin influences the effects of cannabis in a human laboratory model of cannabis use.
Primary Outcome
Number of cannabis puffs participant chooses to smoke.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lorcaserin
- DRUG Marijuana
Study Locations (1)
New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-09-05 |
| Est. Completion | 2021-12-31 |
| Phase | Phase 1 |
What the finished NCT03253926 record still lists
NCT03253926 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 279-participant average among 44 other Cannabis Use trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Cannabis Use appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03253926 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03253926 about?
NCT03253926 is a clinical study titled "Effect of Lorcaserin on Cannabis Withdrawal and Self-administration". In this study, the investigators are interested in testing how lorcaserin influences the effects of cannabis in a human laboratory model of cannabis use.
What is the current status of trial NCT03253926?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2017-09-05. Estimated completion is 2021-12-31.
What conditions does trial NCT03253926 study?
This clinical trial studies the following conditions: Cannabis Use.
What interventions are being tested in trial NCT03253926?
The interventions under investigation include: Placebo (DRUG), Lorcaserin (DRUG), Marijuana (DRUG).
Who is sponsoring clinical trial NCT03253926?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03253926 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis Use
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03253926's enrollment target sits among peer trials
15 43rd of 44 higher than 2 of 44 other Cannabis Use trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cannabis Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Cannabis on Cigarette Use Behavior
RECRUITING · Phase 1
-
SV2A in Older Adults
RECRUITING · Phase 1
-
HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention)
RECRUITING · Phase 1
-
Maternal Choline Supplementation and Cannabis Use During Pregnancy: Impact on Early Brain Development
RECRUITING · Phase 1
-
The Impact of Product Formulation on the Pharmacokinetics and Pharmacodynamics of Cannabis Edibles
RECRUITING · Phase 1
-
Effect of Cannabis on E-Cigarette Use Behavior
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI